Stockscreener 앱 받기
2.09
2.79%
-0.06
전일 마감가:
$2.15
열려 있는:
$2.15
하루 거래량:
21,206
Relative Volume:
0.02
시가총액:
$3.62M
수익:
-
순이익/손실:
$-2.77M
주가수익비율:
-0.7898
EPS:
-2.6464
순현금흐름:
$-2.69M
1주 성능:
-4.13%
1개월 성능:
-19.62%
6개월 성능:
-29.22%
1년 성능:
-51.40%
1일 변동 폭
$2.00
$2.15
1주일 범위
$2.00
$2.3976
52주 변동 폭
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.09 | 3.62M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc 주식(XRTX)의 최신 뉴스
XORTX Therapeutics Inc (XRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Q1 2024 Earnings: Significant EPS Miss Reflects R&D Investment, Stock Gains Despite Loss - newsline.com
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XORTX Therapeutics (XRTX) Slips 0.68% as Traders Eye Key Support at $2.06Covered Call ETF - newsline.com
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO - marketscreener.com
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO - Stock Titan
A 28-year-old co-CEO and XORTX's $700M gout push in the US - Stock Titan
XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing - The Globe and Mail
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - The Manila Times
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | Associated Press | syndication news - Enidnews.com
XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture - Stock Titan
XORTX drops TSX Venture listing to reduce costs, focus on gout drug - Stock Titan
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Stock Chart | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics (XRTX) Slides Over 3% as Biotech Stock Tests Key Support LevelsTrend Reversal Picks - newsline.com
XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading SessionSkew Index - thelegaladvocate.com
XORTX Therapeutics (XRTX) Edges Higher as Stock Holds Above Key SupportAnalyst Upgrade Stocks - newsline.com
XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance LevelFund Manager Survey - newsline.com
XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics Q1 2024 Earnings: Steep EPS Miss Highlights Pre‑Revenue Biotech HurdlesGuidance Upgrade Report - newsline.com
XORTX Therapeutics Raises US$5 Million Via Public Offering - marketscreener.com
XORTX Announces Closing of US$5 Million Public Offering - markets.businessinsider.com
XORTX Therapeutics (NASDAQ: XRTX) closes US$5M share and pre-funded warrant deal - Stock Titan
XORTX raises US$5M, earmarks US$2.5M for investor marketing - Stock Titan
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - The Manila Times
XORTX Therapeutics Inc.Common Shares (NQ: XRTX - FinancialContent
XORTX Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XORTX Therapeutics Inc expected to post a loss of C$1.64 a shareEarnings Preview - TradingView
Here are the top movers in Friday's session. - ChartMill
XORTX (NASDAQ: XRTX) raises ~$4.7M via share sale and pre-funded warrants - Stock Titan
XRTX Announces Public Offering of Shares - GuruFocus
XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9% - marketscreener.com
XORTX (NASDAQ: XRTX) prices US$5M public equity and warrant deal - Stock Titan
Xortx announces US$5 million public offering - marketscreener.com
XORTX Announces US$5 Million Public Offering - The Manila Times
XORTX Announces US$5 Million Public Offering | Associated Press | syndication news - Enidnews.com
[EFFECT] XORTX Therapeutics Inc. SEC Filing - Stock Titan
Kidney drug developer XORTX prices US$5M Nasdaq share sale - Stock Titan
XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold - The Globe and Mail
XORTX (NASDAQ: XRTX) estimates $4.1M equity, above Nasdaq minimum - Stock Titan
Xortx Therapeutics Inc (XRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):